Bispecific antibodies: design, therapy, perspectives. 2018

Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
Laboratory of Repair Enzymes, Siberian Branch of Russian Academy of Sciences Institute of Chemical Biology and Fundamental Medicine, Novosibirsk State University, Novosibirsk, Russia.

Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs - catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.

UI MeSH Term Description Entries
D007155 Immunologic Factors Biologically active substances whose activities affect or play a role in the functioning of the immune system. Biological Response Modifier,Biomodulator,Immune Factor,Immunological Factor,Immunomodulator,Immunomodulators,Biological Response Modifiers,Biomodulators,Factors, Immunologic,Immune Factors,Immunological Factors,Modifiers, Biological Response,Response Modifiers, Biological,Factor, Immune,Factor, Immunological,Factors, Immune,Factors, Immunological,Modifier, Biological Response,Response Modifier, Biological
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D018033 Antibodies, Bispecific Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors. Bifunctional Antibodies,Bispecific Antibodies,Bispecific Monoclonal Antibodies,Antibodies, Bifunctional,Antibodies, Bispecific Monoclonal,Monoclonal Antibodies, Bispecific

Related Publications

Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
February 2021, Cancers,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
August 2019, Antibodies (Basel, Switzerland),
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
April 2010, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
January 1997, Cancer immunology, immunotherapy : CII,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
January 2018, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
May 2000, Cancer journal (Sudbury, Mass.),
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
March 2009, Immunotherapy,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
March 2009, Current opinion in drug discovery & development,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
October 1999, Current opinion in immunology,
Sergey E Sedykh, and Victor V Prinz, and Valentina N Buneva, and Georgy A Nevinsky
October 2021, Bulletin du cancer,
Copied contents to your clipboard!